Vomiting – Talk Bio

Actionable Insights Powered by AI

Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns

3 weeks ago talkbio0Tagged Adverse event, amgen, Clinical Trials, Dosage, Escalation, gastric inhibitory polypeptide receptor, GLP-1 receptor, MariTide, Obesity, Phase 3, Vomiting

Amgen; MariTide; Phase 3; obesity treatment; dose escalation; vomiting; adverse events; clinical trial; GLP-1 receptor; GIP receptor

Roche’s Obesity Pill Candidate Faces Safety Concerns Amid Promising Efficacy Results

10 months ago talkbio0Tagged aspects of adverse effects, concerns, Contraceptives, Oral, CT-996, Effectiveness, Gastrointestinal Issues, Nausea, Obesity, Roche (company), Safety, Vomiting

Roche, Obesity Pill, Safety Concerns, Efficacy Data, CT-996, Side Effects, Nausea, Vomiting, Gastrointestinal Issues